Explore

TrendlineTrendline
Oyster Therapeutics Secures $60 Million Series A Funding to Advance Alzheimer's Drug Development

Oyster Therapeutics Secures $60 Million Series A Funding to Advance Alzheimer's Drug Development

Oyster Therapeutics Secures $60 Million Series A Funding to Advance Alzheimer's Drug Development
Rapid ReadRapid Read
Mass General Brigham Researchers Highlight Tailored iPSC-Based Therapies for Neurodegenerative Diseases

Mass General Brigham Researchers Highlight Tailored iPSC-Based Therapies for Neurodegenerative Diseases

Researchers at Mass General Brigham have emphasized that induced pluripotent stem cell (iPSC)-based therapies for neurodegenerative diseases must be tailored to the specific biology of each condition. Their review, spanning 20 years of iPSC research, indicates that a single therapeutic strategy is unlikely to be effective for all neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). The research highlights that PD is the most advanced model for neuronal replacement due to its well-defined cell loss, while HD, AD, and ALS present more complex challenges requiring combinations of cell replacement, cellular support, immune modulation, or engineered therapeutic delivery. The study also focuses on the critical period after cell delivery, referred to as a 'biological black box,' where factors like injury, immune responses, tissue remodeling, and integration significantly influence the fate of transplanted cells...
TrendlineTrendline
Alpha Cognition Appoints Caren Deardorf to Board of Directors, Bolstering Commercial Strategy for Alzheimer's Drug

Alpha Cognition Appoints Caren Deardorf to Board of Directors, Bolstering Commercial Strategy for Alzheimer's Drug

Alpha Cognition Appoints Caren Deardorf to Board of Directors, Bolstering Commercial Strategy for Alzheimer's Drug
Rapid ReadRapid Read
Alpha Cognition Reports Strong Q3 2026 Financial Results and ZUNVEYL Growth for Alzheimer's Treatment

Alpha Cognition Reports Strong Q3 2026 Financial Results and ZUNVEYL Growth for Alzheimer's Treatment

Alpha Cognition Inc., a biopharmaceutical company, has announced its financial results for the third quarter ended September 30, 2026, highlighting significant growth in its Alzheimer's treatment, ZUNVEYL. Net product revenue for ZUNVEYL increased by approximately 30% quarter-over-quarter to $7.8 million, and over 230% year-over-year. The number of ZUNVEYL bottles dispensed rose by about 31% sequentially to 10,896, with over 30,000 prescriptions filled since its launch. The company also exceeded its full-year 2026 goal for cumulative prescribers, reaching 2,410 a quarter early. Michael McFadden, Chief Executive Officer of Alpha Cognition, stated that the third quarter was the strongest since ZUNVEYL's launch, attributing the success to strong demand growth, record prescriber and facility adoption, and disciplined operating spending. The company also reported initial results from its CONVERGE real-world evidence program, showing that 79.1% of new ZUNVEYL users reached a therapeutic dose within 180 days, com...
Rapid ReadRapid Read
Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche has announced the initiation of a new Phase II clinical trial, TARBELA-AD, to evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer's disease. This study is part of Roche's broader strategy to address Alzheimer's by targeting various biological mechanisms, specifically focusing on neuroinflammation as a key driver of pathology in addition to amyloid aggregation. The announcement was made in anticipation of the 19th Clinical Trials on Alzheimer's Disease (CTAD) Congress in Boston, scheduled from November 16-19, 2026. According to Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer, this trial aims to test additional therapeutic hypotheses to potentially halt or prevent disease progression, complementing their ongoing trontinemab programs. Roche's diagnostics division is also expanding access to earlier and more accurate Alzheimer's diagnosis through its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests.
Rapid ReadRapid Read
Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals Inc. announced it will present two data presentations related to Alzheimer's disease psychosis (ADP) and its investigational drug, remlifanserin, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. The presentations will include findings from the Phase 2 portion of the ongoing RADIANT clinical trial program, which evaluates remlifanserin in patients with ADP. An oral presentation will detail the efficacy and safety of remlifanserin, while a poster presentation will examine biomarker heterogeneity among patients meeting clinical criteria for ADP. Remlifanserin is a novel, highly selective 5-HT2A receptor inverse agonist being developed to treat psychosis associated with Alzheimer's disease and Lewy body dementia. Currently, there is no FDA-approved drug specifically for the treatment of Alzheimer's disease psychosis.
Rapid ReadRapid Read
USC and Indiana University Collaborate on Alzheimer's Disease Research and Clinical Trials

USC and Indiana University Collaborate on Alzheimer's Disease Research and Clinical Trials

The University of Southern California (USC) and Indiana University (IU) are engaged in extensive collaborative research focused on Alzheimer's disease and other dementia-related conditions. USC's Keck School of Medicine Professor of Neurology Paul Aisen, who also directs the USC Epstein Family Alzheimer's Therapeutic Research Institute, is working with multiple IU School of Medicine colleagues on various projects. These include the Alzheimer's Plasma Extension Study, which tracks Alzheimer's-related blood biomarkers and cognitive function, and the Alzheimer's Clinical Trials Consortium, a network designed to foster innovation in disease research. Additionally, collaborations extend to the Alzheimer's Tau Platform clinical trial, evaluating new treatments to reduce protein buildup in the brain, and the Longitudinal Follow-up of Clinical Trial Participants for Brain Donation. USC Professor of Clinical Neurology Michael S. Rafii has also partnered with IU researchers on a clinical trial to prevent Alzheimer's...
Rapid ReadRapid Read
New Retinal Imaging Method Detects TDP-43 Pathology in Neurodegenerative Diseases

New Retinal Imaging Method Detects TDP-43 Pathology in Neurodegenerative Diseases

Researchers have developed a novel method utilizing a fluorescent ocular tracer, AMDX-8050, to detect TDP-43 pathology in the retina, a key biomarker for several neurodegenerative diseases. This new technique, detailed in a study, aims to provide a simple and non-invasive way to identify conditions such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE). The study involved examining cadaveric retinal tissues from individuals with ALS, FTD-TDP-43, and LATE. AMDX-8050 successfully labeled cytoplasmic retinal deposits that co-localized with TDP-43 pathology, showing a dense and varied distribution similar to those found in matched spinal cord and motor cortex tissues. This development suggests a potential new class of retinal tracers with broad applicability for TDP-43 proteinopathies, offering a promising avenue for earlier diagnosis and monitoring of these complex diseases. The research was supported by organizations includi...
TrendlineTrendline
Alpha Cognition Inc. Strengthens Board with Caren Deardorf Appointment Amidst Alzheimer's Treatment Development

Alpha Cognition Inc. Strengthens Board with Caren Deardorf Appointment Amidst Alzheimer's Treatment Development

Alpha Cognition Inc. Strengthens Board with Caren Deardorf Appointment Amidst Alzheimer's Treatment Development
Rapid ReadRapid Read
Eli Lilly's Retatrutide Shows Significant Reduction in Knee Osteoarthritis Pain and Weight in TRIUMPH Trials

Eli Lilly's Retatrutide Shows Significant Reduction in Knee Osteoarthritis Pain and Weight in TRIUMPH Trials

Eli Lilly's investigational drug, retatrutide, a triple agonist of GIP, GLP-1, and glucagon receptors, has demonstrated significant efficacy in reducing knee osteoarthritis pain and body weight in two Phase 3 trials, TRIUMPH-4 and TRIUMPH-1-OA. In TRIUMPH-4, 69.6% of participants on 9 mg and 63.2% on 12 mg achieved at least a 50% reduction in WOMAC pain, compared to 37.8% with placebo. Similarly, WOMAC physical function scores improved significantly. In TRIUMPH-1-OA, mean weight change at week 80 ranged from -17.5% with 4 mg to -24.8% with 12 mg, versus -4.3% with placebo. The most common adverse events were gastrointestinal, including nausea, diarrhea, and constipation, primarily during dose escalation. Discontinuation rates due to adverse events were higher in the retatrutide groups compared to placebo. Serious adverse events were also more frequent with retatrutide. The trials, funded by Eli Lilly, excluded patients requiring knee replacement and were not designed to assess osteoarthritis progression.
TrendlineTrendline
Novo-Backed Windward Bio Targets $1 Billion Valuation in U.S. IPO Amidst Strong Biotech Market

Novo-Backed Windward Bio Targets $1 Billion Valuation in U.S. IPO Amidst Strong Biotech Market

Novo-Backed Windward Bio Targets $1 Billion Valuation in U.S. IPO Amidst Strong Biotech Market
TrendlineTrendline
Latham Watkins Advises on Abeona Therapeutics' $30 Million Private Placement

Latham Watkins Advises on Abeona Therapeutics' $30 Million Private Placement

Latham Watkins Advises on Abeona Therapeutics' $30 Million Private Placement